Biochemical and genetic markers in liver diseases
Recruiting
- Conditions
- K70-K77Diseases of liver
- Registration Number
- DRKS00031527
- Lead Sponsor
- niversitätsklinikum Heidelberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Liver disease
Exclusion Criteria
Lack of legal capacity, lack of consent, prison, patients < 18 years
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Descriptive assessment of patients with liver disease, with respect to course of disease, clinical parameters and survival - related to biochemical and genetic parameters
- Secondary Outcome Measures
Name Time Method Follow-up of patients in regular intervals
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do PNPLA3 and TM6SF2 genetic variants influence non-alcoholic steatohepatitis progression in DRKS00031527?
What novel biomarkers identified in DRKS00031527 outperform traditional markers like FibroScan for liver fibrosis staging?
How do HFE mutation profiles correlate with treatment response in hemochromatosis patients from DRKS00031527?
What adverse event patterns are associated with specific genetic markers in DRKS00031527 liver disease cohort?
How might DRKS00031527 findings inform combination therapies for antiviral-resistant hepatitis C subtypes?